Chloroquine and hydroxychloroquine as inhibitors of human immunodeficiency virus (HIV-1) activity

Current Pharmaceutical Design

Volumn 10, Issue 21, 2004, Pages 2643-2648

  Romanelli, Frank ^a   Smith, Kelly M ^a   Dee Hoven, Ardis ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Chloroquine; HIV; Hydroxychloroquine; Malaria; Treatment

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; AMPRENAVIR; AMPRENAVIR PHOSPHATE; ANTIRETROVIRUS AGENT; ATAZANAVIR; CD4 ANTIGEN; CHLOROQUINE; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; FORTAVASE; GLYCOPROTEIN GP 120; HYDROXYCHLOROQUINE; HYDROXYUREA; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; MEPACRINE; NELFINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIDEX EC; ZALCITABINE; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; CELL COUNT; CLINICAL TRIAL; CONCENTRATION RESPONSE; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; EYE DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; IN VIVO STUDY; MALARIA; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; URTICARIA; VIRUS INHIBITION; VIRUS LOAD; VIRUS REPLICATION;

ANIMALS; ANTI-HIV AGENTS; ANTIMALARIALS; CHLOROQUINE; CLINICAL TRIALS; HIV-1; HUMANS; HYDROXYCHLOROQUINE;

EID: 3242876082     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612043383791     Document Type: Article

References (30)

1. CDC. HIV/AIDS surveillance report, 2001; 13 (no.2).
2. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Panel on Clinical Practice for Treatment of HIV Infection convened by the Department of Health and Human Services (DHHS) and the Henry J. Kaiser Family Foundation. July 14, 2003. http: //www.aidsinfo.nih.gov/guidelines (accessed August 11, 2003).
3. Savarino A, Gennero L, Sperber K, et al. The anti-HIV activity of chloroquine. Journal of Clinical Virology 2001; 20: 131-5.
4. Mackenzie AH, Scherbel AL. Chloroquine and hydroxychloroquine in rheumatological therapy. Clin Rheum Dis 1980; 6: 545-566.
5. Rynes RI. Ophthalmologic considerations in using antimalarials in the United States. Lupus 1996; 5: S73-4.
6. Boelart JR, Piette J, Sperber K. The potential place of chloroquine in the treatment of HIV-1-infected patients. Journal of Clinical Virology 2001; 20: 137-40.
7. Stein BS, Gowda SD, Lifson JD, et al. pH independent HIV entry into CD4-positive cells via virus envelope fusion to plasma membrane. Cell 1987; 49: 659-668.
8. Fesen MR, Kohn KW, Leteurtre F, et al. Inhibitors of human immunodeficiency virus integrase. Proc Natl Acad Sci USA 1993; 90: 2399-2403.
9. Jiang MC, Lin JK, Chen SS. Inhibition of HIV-1 Tat-mediated transactivation by quinacrine and chloroquine. Biochemical and Biophysical Research Communications 1996; 226: 1-7.
10. Tsai WP, Nara PL, Kung HF, et al. Inhibition of human immunodeficiency virus infectivity by chloroquine. AIDS Research and Human Retroviruses 1990, 6: 481-489.
11. Sperber K, Kalb TH, Stecher VJ, et al. Inhibition of human immunodeficiency virus type 1 replication by hydroxychloroquine in T cells and monocytes. AIDS Research and Human Retroviruses 1993; 9: 91-98.
12. Pardridge WM, Yang J, Diagne A. Chloroquine inhibits HIV-1 replication in human peripheral blood lymphocytes. Immunology Letters 1998; 64: 45-7.
13. Chiang G, Sassaroli M, Louie M, et al. Inhibition of HIV-1 replication by hydroxychloroquine: mechanism of action and comparison with zidovudine. Clinical Therapeutics 1996; 18: 1080-1092.
14. Boelaert JR, Sperber K, Piette J. Chloroquine exerts an additive in vitro anti-hiv type 1 effect when associated with didanosine and hydroxyurea. AIDS Research and Human Retroviruses 1999; 1241-7.
15. Romanelli F, Pomeroy C, Smith KM. Hydroxyurea to inhibit human immunodeficiency virus-1 replication. Pharmacotherapy 1999; 19(2): 196-204.
16. Boelaert JR, Sperber K, Piette J. The additive in vitro anti-HIV-1 effect of chloroquine, when combined with zidovudine and hydroxyurea. Biochemical Pharmacology 2001; 61: 1531-5.
17. Savarino A, Gennero L, Chen HC, et al. Anti-hiv effects of chloroquine: mechanisms of inhibition and spectrum of activity. AIDS 2001; 15: 2221-2229.
18. Sperber K, Louie M, Kraus T, et al. Hydroxychloroquine treatment of patients with human immunodeficiency virus type 1. Clinical Therapeutics 1995; 17: 622-36.
19. Heimlich HJ, Chen XP, Xiao BQ, et al. Malariotherapy for HIV patients. Mechanisms of Aging and Development 1997; 93: 79-85.
20. Sperber K, Chiang G, Chen H, et al. Comparison of hydroxychloroquine with zidovudine in asymptomatic patients infected with human immunodeficiency virus type 1. Clinical Therapeutics 1997; 19: 913-923.
21. Patton NI, Adoulhab J, Karim F. Hydroxychloroquine, hydroxycarbamide, and didanosine as economic treatment for HIV-1. Lancet 2002; 359: 1667-8.
22. Ornstein MH, Sperber K. The anti-inflammatory and antiviral effects of hydroxychloroquine in two patients with acquired immunodeficiency syndrome and acute anti-inflammatory arthritis. Arthritis and Rheumatism 1996; 39: 157-61.
23. Cohen H, ed. Drug Topics Red book. Montvale NJ: Medical Economics, 2003.
24. Crowle AJ, May MH. Inhibition of tubercle bacilli in cultured human macrophages by chloroquine used alone and in combination with streptomycin, isoniazid, pyrazinamide, and two metabolites of vitamin D3. Antimicrob Agents Chemother 1990; 34: 2217-22.
25. Newman SL, Gootee L, Brunner G, et al. Chloroquine induces human macrophage killing of histoplasma capsulatum by limiting the availability of intracellular iron and is therapeutic in a murinie model of histoplasmosis. J Clin Invest 1994; 93: 1422-9.
26. Levitz SM, Harrison TS, Tabuni A, et al. Chloroquine induces human mononuclear phagocytes to inhibit and kill Cryptococcus neoformans by a mechanism independent of iron deprivation. J Clin Invest 1997; 100: 1640-6.
27. Boelaert JR, Taro S, Augustijins P, et al. Chloroquine accumulates in breast-milk cells: potential impact in the prophylaxis of postnatal mother-to-child transmission. AIDS 2001; 2205-7.
28. Nair V. Novel inhibitors of HIV integrase: the discovery of potential anti-HIV therapeutic agents. Curr Pharm Design 2003; 9(31): 2553-65.
29. Romanelli F, Pomeroy C. Concurrent use of antiretrovirals and anticonvulsants in human immunodeficiency virus (HIV) seropositive patients. Curr Pharm Design 2003; 9(18): 1433-9.
30. Rosenthal PJ, Sijwali PS, Singh A, Shenai BR. Cysteine proteases of malaria parasites: targets for chemotherapy. Curr Pharm Design 2002; 8(18): 1659-72.